Patents by Inventor Abdellah Tahri

Abdellah Tahri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibacterial Compounds
    Publication number: 20240132470
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: November 29, 2023
    Publication date: April 25, 2024
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Antibacterial compounds
    Patent number: 11866419
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: January 9, 2024
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    Publication number: 20230091047
    Abstract: The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).
    Type: Application
    Filed: March 13, 2020
    Publication date: March 23, 2023
    Inventors: Sandrine Céline GROSSE, Jan Martin BERKE, Meng-yang HSIAO, Lili HU, Edgar JACOBY, Tim Hugo Maria JONCKERS, Bart Rudolf Romanie KESTELEYN, Stefaan Julien LAST, Carlolina MARTINEZ LAMENCA, Mathieu PERRIER, Serge Maria Aloysius PIETERS, Pierre Jean-Marie Bernard RABOISSON, Abdellah TAHRI, Koen VANDYCK, Wim Gaston VERSCHUEREN
  • Antibacterial Compounds
    Publication number: 20230014173
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 19, 2023
    Applicant: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • FUSED HETEROCYCLE DERIVATIVES
    Publication number: 20220242879
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: May 27, 2020
    Publication date: August 4, 2022
    Inventors: Scott D. KUDUK, Christelle Catherine Cecile DOEBELIN, Abdellah TAHRI, Sandrine Céline GROSSE, Stefaan Julien LAST, Lindsey Graham DERATT, Koen VANDYCK, Pierre Jean-Marie Bernard RABOISSON, Jan Martin BERKE, Wim Gaston VERSCHUEREN, Michel OBRINGER
  • Spirothietane nucleosides
    Patent number: 11267844
    Abstract: The present invention relates to 2?-spirothietane nucleosides, and the phosphates and the prodrugs thereof, and the pharmaceutically acceptable salts and solvates thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The invention also relates to processes for the preparation of the compounds.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Abdellah Tahri, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson
  • Heterocyclic compounds as antibacterials
    Patent number: 11179396
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Antibacterial compounds
    Patent number: 11180472
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
    Patent number: 11096931
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Stefaan Julien Last, Bart Rudolf Romanie Kesteleyn, Sandrine Céline Grosse, Tim Hugo Maria Jonckers, Jan Martin Berke, Geerwin Yvonne Paul Haché, Edgar Jacoby, Carolina Martinez Lamenca, Morgan Charles R. Lecomte, Abdellah Tahri, Sarah Sauviller, Karen Maria Vergauwen
  • Piperazine derivatives for influenza virus inhibitions
    Patent number: 11040963
    Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 22, 2021
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Maria Van Dongen, Jaroslaw Juraszek, Griet Wim Bert Schepens, Charles Edward Lawson, Brian Shook, Maria Tim Hugo Jonckers, Abdellah Tahri, Bernard Pierre Jean-Marie Raboisson, Nestor CHristophe Francis Robert Buyck
  • SPIROTHIETANE NUCLEOSIDES
    Publication number: 20210139524
    Abstract: The present invention relates to 2?-spirothietane nucleosides, and the phosphates and the prodrugs thereof, and the pharmaceutically acceptable salts and solvates thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The invention also relates to processes for the preparation of the compounds.
    Type: Application
    Filed: August 31, 2018
    Publication date: May 13, 2021
    Inventors: Abdellah Tahri, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson
  • HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS
    Publication number: 20200308169
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 1, 2020
    Applicant: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Uracyl spirooxetane nucleosides
    Patent number: 10774106
    Abstract: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES
    Publication number: 20200268730
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 27, 2020
    Inventors: Stefaan Julien LAST, Bart Rudolf Romanie KESTELEYN, Sandrine Céline GROSSE, Tim Hugo Maria JONCKERS, Jan Martin BERKE, Geerwin Yvonne Paul HACHÉ, Edgar JACOBY, Carolina MARTINEZ LAMENCA, Morgan Charles R. LECOMTE, Abdellah TAHRI
  • ANTIBACTERIAL COMPOUNDS
    Publication number: 20200239434
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: April 14, 2020
    Publication date: July 30, 2020
    Applicant: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
    Patent number: 10654837
    Abstract: Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhao-Kui Wan, Haibing Guo, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • URACYL SPIROOXETANE NUCLEOSIDES
    Publication number: 20200109161
    Abstract: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 9, 2020
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Uracyl spirooxetane nucleosides
    Patent number: 10544184
    Abstract: The present invention relates to compound of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also related to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 28, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • PIPERAZINE DERIVATIVES FOR INFLUENZA VIRUS INHIBITIONS
    Publication number: 20200010459
    Abstract: The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity while having low cytotoxity. Furthermore, the present invention relates to pharmaceutical compositions comprising said piperazine derivatives, methods of preparing said piperazine derivatives, as well as said piperazine derivatives for use in medical prevention or treatment, especially for preventing or treating influenza.
    Type: Application
    Filed: February 1, 2018
    Publication date: January 9, 2020
    Inventors: Maria VAN DONGEN, Jaroslaw JURASZEK, Griet Wim Bert SCHEPENS, Charles Edward LAWSON, Brian SHOOK, Maria Tim, Hugo JONCKERS, Abdellah TAHRI, Bernard Pierre, Jean-Marie RABOISSON, Nestor CHristophe, Francis, Robert BUYCK
  • Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
    Patent number: 10501445
    Abstract: Quinoxalinones and dihydroquinoxalinones having inhibitory activity on RSV replication and having the formula I including addition salts, and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: Abdellah Tahri, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Samuel Dominique Demin